December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ:ALVO)

5.995 -0.145 (-2.36%)
Delayed Quote Updated: 12:04 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Alvotech - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
From Alvotech
Via GlobeNewswire
News headline image
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to present at upcoming investor conferences in September
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to Report Financial Results for H1 2026
From Alvotech
Via GlobeNewswire
News headline image
Alvotech announces successful closure of FDA inspection of manufacturing facility
From Alvotech
Via GlobeNewswire
News headline image
Alvotech further strengthens liquidity by securing term loan facility of $75 million
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
From Alvotech
Via GlobeNewswire
News headline image
Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
From Alvotech
Via GlobeNewswire
News headline image
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
From Alvotech
Via GlobeNewswire
News headline image
Main Results of 2026 Annual and Extraordinary General Meeting
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to present at upcoming investor conferences in June
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Q1 2026 Financial Results
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces a Change in its Executive Team
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to Report Financial Results for the First Quarter of 2026
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Files Annual Report with the SEC
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Q4 2025 and Full Year 2025 Financial Results
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results
From Alvotech
Via GlobeNewswire
News headline image
ALVO INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alvotech
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
From Alvotech
Via GlobeNewswire
News headline image
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg
From Alvotech
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Continues Investigations into Alvotech and Beyond Meat on Behalf of Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.